Physician profile
Jackline Sutherland
NPI 1861882029
$3,041.24
in general payments reported to CMS, 2019-2025
18 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $262 · 2023: $383 · 2024: $1,093 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $850.16 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $674.43 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $452.56 | 2022-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $302.19 | 2021-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $245.45 | 2022-2025 | |
| Pfizer INC. | $109.93 | 2023-2025 | |
| Abbvie INC. | $91.80 | 2021-2025 | |
| Amgen INC. | $62.91 | 2023-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.40 | 2023-2024 | Jardiance, Stiolto Respimat |
| Glaxosmithkline, LLC. | $39.40 | 2022-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $29.75 | 2024 | Voquezna |
| Dexcom, INC. | $24.99 | 2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $23.67 | 2023 | Dupixent |
| Viiv Healthcare Company | $23.37 | 2021 | |
| Exact Sciences Corporation | $17.09 | 2025 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.68 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.42 | 2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackline Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.